跳至主要内容
临床试验/NCT05084092
NCT05084092招募中2 期

IORT After Surgical Resection of Brain Metastases: Feasibility and Efficacy Phase II Trial

Institut Català d'Oncologia2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年6月17日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
40
试验地点
2
主要终点
Median local progression free survival (PFS)

研究概览

简要总结

To evaluate the feasibility and efficacy of the Intraoperative Radiation Therapy (IORT) after the resection of a brain metastases to reduce the incidence of local relapse

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years, Karnofsky Performance Index ≥
  • Newly diagnosed cerebral or cerebellar lesion (contrast enhancing on a T1- weighted MRI scan) amenable to total resection with no dural attachment.
  • Frozen section confirming a metastasis of an extracranial (i.e. non-CNS) tumor.
  • Adequate distance to optic nerve(s), chiasm and brainstem (organs at risk for radiotherapy).
  • Adequate birth control.
  • Informed consent.

排除标准

  • Leptomeningeal spread and dural attachment (assessed pre- and intraoperative).
  • Frozen section reveals primary CNS tumor, lymphoma, SCLC or germinoma.
  • Psychiatric or social condition potentially interfering with compliance.
  • Contraindication against anesthesia, surgery, MRI and/or contrast agents.
  • Pregnant or breast-feeding women.

结局指标

主要结局

Median local progression free survival (PFS)

时间窗: 12 months

Time span (in months) between surgery and recurrence within a 0,5 cm margin around the resection cavity, evaluated through Response Assessment in Neuro-Oncology (RANO) criteria for brain metastasis obtained from serial Magnetic resonance imaging (MRI) scans.

次要结局

  • Median time to the initiation of systemic therapies(12 months)
  • Median overall survival (OS)(12 months)
  • Median regional PFS (rPFS)(12 months)
  • Change in neurocognitive performance (compared to baseline): Repetition(6, and 12 months)
  • Radiation-related (acute / early delayed / late) neurotoxicity(12 months)
  • Change in neurocognitive performance (compared to baseline): Minimental(6, and 12 months)
  • Global PFS (gPFS)(12 months)
  • Quality of life (QoL)(6, and 12 months)
  • Change in neurocognitive performance (compared to baseline): Semantic(6, and 12 months)
  • Change in neurocognitive performance (compared to baseline): Trail making(6, and 12 months)
  • Change in neurocognitive performance (compared to baseline): Oral(6, and 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验